PSYCHIATRIE PRO PRAXI / Psychiatr. praxi. 2023;24(2):123-130 / www.psychiatriepropraxi.cz 130 ZAZNĚLO NA 65. KONFERENCI ČNPS V MARIÁNSKÝCH LÁZNÍCH Sekvenční léčba schizofrenie jsou hospitalizováni déle než 1 rok. Ukazuje se, že z 2 000 pacientů má asi 20 % pacientů tak závažnou symptomatologii, že potřebují dlouhodobou zdravotní péči a není tedy pravdou, že v psychiatrických zařízeních jsou jen pacienti ze sociálních důvodů. Profesor Kašpárek sdělil, že tato data máme poměrně recentně a máme možnost s nimi pracovat a říct si, jaká by měla být kapacita jednotlivých prvků péče. Je to program práce pro výbor společnosti a pro ministerstvo pro letošní rok, s cílem nasměrovat zdroje tam, kde jsou potřeba, jednak aby pacienti dostali péči, když ji potřebují, a aby segmenty, které máme špatně rozvinuté, měly dostatečnou kapacitu a nebyly přetížené. Profesor Kašpárek své sdělení ukončil přáním, aby se nejednalo jenom o reformu na papíře, ale aby se doopravdy podařilo ji zrealizovat. LITERATURA 1. Levitan B, Markowitz M, Mohamed AF, et al. Patients‘ Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. Psychiatr Serv. 2015 Jul;66(7):719-26. doi: 10.1176/appi.ps.201400188. Epub 2015 Mar 16. PMID: 25772762. 2. Achtyes E, Simmons A, Skabeev A, et al. Patient preferences concerning the efficacy and side‑effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry. 2018 Sep 12;18(1):292. doi: 10.1186/ s12888-018-1856-y. PMID: 30223804; PMCID: PMC6142379. 3. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double‑blind, placebo- and olanzapine‑controlled study. Am J Psychiatry. 2011 Sep;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907. Epub 2011 Jun 15. PMID: 21676992. 4. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open‑label, extension study. J Clin Psychiatry. 2013 May;74(5):507-15. doi: 10.4088/JCP.12m08084. Epub 2013 Mar 13. PMID: 23541189. 5. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta‑analysis. Lancet Psychiatry. 2020 Jan;7(1):64-77. doi: 10.1016/S2215-0366(19)30416-X. Epub 2019 Dec 17. PMID: 31860457; PMCID: PMC7029416. 6. Mattingly GW, Haddad PM, Tocco M, et al. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open‑label study. BMC Psychiatry. 2020 May 5;20(1):199. doi: 10.1186/s12888-020-02523-1. PMID: 32370778; PMCID: PMC7201608. 7. Huhn M, Nikolakopoulou A, Schneider‑Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi‑episode schizophrenia: a systematic review and network meta‑analysis. Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S01406736(19)31135-3. Epub 2019 Jul 11. Erratum in: Lancet. 2019 Sep 14;394(10202):918. PMID: 31303314; PMCID: PMC6891890. 8. Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig. 2018 Jan 10;36(1):/j/hmbci.2018. 36. issue-1/ hmbci-2017-0065/hmbci-2017-0065.xml. doi: 10.1515/hmbci-2017-0065. PMID: 29320364; PMCID: PMC6818518. 9. Nicol GE, Kolko R, Lenze EJ, et al. Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic‑Treated Youth: A Randomized Pilot Study. J Child Adolesc Psychopharmacol. 2019 Aug;29(6):439-447. doi: 10.1089/cap.2018.0120. Epub 2019 Apr 17. PMID: 30994376; PMCID: PMC6661918. 10. McWhinney S, Kolenic M, Franke K, et al. Obesity as a Risk Factor for Accelerated Brain Ageing in First‑Episode Psychosis‑A Longitudinal Study. Schizophr Bull. 2021 Oct 21;47(6):1772-1781. doi: 10.1093/schbul/sbab064. PMID: 34080013; PMCID: PMC8530396. 11. Siafis S, Davis JM, Leucht S. Antipsychotic drugs: from ‚major tranquilizers‘ to Neuroscience‑based‑Nomenclature. Psychol Med. 2021 Feb;51(3):522-524. doi: 10.1017/ S0033291719003957. Epub 2020 Jan 8. PMID: 31910928. 12. Baldez DP, Biazus TB, Rabelo‑da‑Ponte FD, et al. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta‑analyses of randomized controlled trials. Neurosci Biobehav Rev. 2021 Jul;126:265-275. 13. Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post ‑hoc analysis of a long‑term, double‑blind continuation study. Schizophr Res. 2015 Aug;166(1-3):334-8 14. Hagi K, Nosaka T, Dickinson D, et al. Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta ‑analysis. JAMA Psychiatry. 2021 May 1;78(5):510-518. doi: 10.1001/jamapsychiatry.2021.0015. PMID: 33656533; PMCID: PMC7931134. 15. Pochiero I, Calisti F, Comandini A, et al. Impact of Lurasidone and Other Antipsychotics on Body Weight: Real‑World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. Int J Gen Med. 2021 Jul 31;14:4081-4094. 16. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open‑label, extension study. J Clin Psychiatry. 2013 May;74(5):507-15. 17. Mattingly GW, Haddad PM, Tocco M, et al. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open‑label study. BMC Psychiatry. 2020 May 5;20(1):199. 18. Etchecopar‑Etchart D, Korchia T, Loundou A, et al. Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta‑Analysis. Schizophr Bull. 2021 Mar 16;47(2):298-308. 19. Huhn M, Nikolakopoulou A, Schneider‑Thoma J, et al. Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi‑Episode Schizophrenia: A Systematic Review and Network Meta‑Analysis. Focus (Am Psychiatr Publ). 2020 Oct;18(4):443-455. 20. Gregory A, Mallikarjun P, Upthegrove R. Treatment of depression in schizophrenia: systematic review and meta ‑analysis. Br J Psychiatry. 2017 Oct;211(4):198-204. 21. Tiihonen J, Tanskanen A, Taipale H. 20-Year Nationwide Follow‑Up Study on Discontinuation of Antipsychotic Treatment in First‑Episode Schizophrenia. Am J Psychiatry. 2018 Aug 1;175(8):765-773. 22. Ostuzzi G, Vita G, Bertolini F, et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia‑spectrum disorders who are clinically stable: a systematic review and network meta‑analysis. Lancet Psychiatry. 2022 Aug;9(8):614-624. 23. Liu CC, Takeuchi H. Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose‑Reduction Algorithm. CNS Drugs. 2020 Feb;34(2):117-126. doi: 10.1007/s40263-019-00682-8. PMID: 31741178. 24. Thornicroft G, Tansella M, Antonelli R. The Lancet Mortality in schizophrenia: a meta-analysis. 2005;365(9460):589-599. ERRATUM Omlouváme se za chybné uvedení, že článek MUDr. Jonáše Bočka – Manická epizoda po prodělání covid-19 pneumonie (Pediatr. praxi. 2023;24(1):43-45), publikovaný v časopise Psychiatrie pro praxi 1/2023, byl zpracován na základě přednášky prof. MUDr. Libora Ustohala, Ph.D. Jedná se o původní článek autora. Redakce
RkJQdWJsaXNoZXIy NDA4Mjc=